Efalizumab in the treatment of psoriasis

Dermatologic Therapy
Craig L Leonardi

Abstract

Efalizumab is a humanized, monoclonal antibody, which targets CD11a, one of the subunits of leukocyte function-associated antigen-1. Administered subcutaneously once weekly, it decreases the activation of T lymphocytes as a primary or secondary process and interferes with the trafficking of T cells into sites of inflammation. Clinically, improvement in psoriasis can be observed as early as two to four weeks. The percent of patients experiencing a 75% reduction in PASI (PASI-75) was 27%, 44%, 47% at 12 weeks, 24 weeks, and 24 months, respectively. During the trials, the safety profile was highly favorable, with minor headaches and myalgias occurring after the initial doses. Rebound on abrupt discontinuation can be problematic for some patients and avoided by transition to an alternative therapy. Efalizumab appears to be a valuable option for patients requiring long-term control of their psoriasis.

References

Mar 1, 1993·Journal of the American Academy of Dermatology·G D Weinstein, G M White
May 29, 2000·Journal of Pharmacokinetics and Biopharmaceutics·R J BauerM R Garovoy
Oct 19, 2001·Journal of the American Academy of Dermatology·K PappM R Garovoy
Dec 12, 2001·The British Journal of Dermatology·A D Ormerod
Aug 16, 2002·Transplant Immunology·Russell L DedrickMarvin Garovoy
Nov 25, 2003·The New England Journal of Medicine·Mark LebwohlUNKNOWN Efalizumab Study Group
Dec 18, 2003·JAMA : the Journal of the American Medical Association·Kenneth B GordonUNKNOWN Efalizumab Study Group

❮ Previous
Next ❯

Citations

Aug 13, 2005·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·J C Prinz
May 3, 2005·Journal of Dermatological Science·John Koo, Pooja Khera
Jan 11, 2011·Expert Opinion on Drug Safety·Marina TalamontiSergio Chimenti
Sep 13, 2006·The British Journal of Dermatology·A M ThielenJ H Saurat
Oct 13, 2006·The Australasian Journal of Dermatology·Michael R Lee, Alan J Cooper
Jan 4, 2007·The British Journal of Dermatology·N KlugerD Bessis
Apr 26, 2006·Journal of the American Academy of Dermatology·Timothy H ClaytonMark D J Goodfield
Apr 14, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·C AntoniouA Katsambas
Oct 1, 2012·Therapeutic Advances in Drug Safety·Fariha Zaheer, Joseph R Berger
Aug 8, 2006·Biotechnology Journal·Theo Dingermann, Ilse Zündorf
Jul 27, 2005·Pharmazie in unserer Zeit·Ilse ZündorfTheo Dingermann
Jan 24, 2007·Journal of Cutaneous Medicine and Surgery·Aditya K Gupta, Andréa M Cherman
Jun 16, 2005·Southern Medical Journal·Karen H Costenbader, Jonathan S Coblyn
Aug 30, 2008·Clinics in Dermatology·Yi-Yang Yvonne LiMichael P Schön

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.